Annual Report 2012 - Acino

22
ACINO | OUR BUSINESSES
Financial performance
(in EUR million)
Sales Cont. margin
40.3 67.6 7.6 4.0
2011 2012 2011 2012
TM share of Group results
26% of
sales
8% of
contribution margin
Top products
• Fentanyl (pain)
• Diclofenac
(nonsteroidal anti-inflammatory)
• Amoxiclav (antibiotic)
In development
• Contraception patch
(customer project)
Technology Marketing:
Full-service from a single partner, from us
what we do
As a partner of pharmaceutical companies worldwide, Acino provides customized onestop
solutions from product development and registration to contract manufacturing,
packaging and logistics.
Market opportunity
The need to boost innovation and protect the leading brands creates a challenge for many
pharmaceutical companies. The primary focus of research-driven pharmaceutical companies
is often on the discovery of new chemical entities and clinical development. Acino fills
the gap by offering a vast range of specialized contract services, all from a single source.
Customized one-stop solutions for pharmaceutical partners
At Acino, we go beyond innovative technologies. We offer fully integrated services from
sourcing of active ingredients and excipients, to development of the formulation, registration,
commercial scale manufacturing and packaging. In close cooperation with our pharmaceutical
partner companies, we customize every step in the value chain, delivering
high-quality products and services at every stage. Everything from a single source – from
us, from Acino.
Key customer-project nearing market readiness
Acino’s Partner Bayer HealthCare announced that it has submitted an application for marketing
authorization in the European Union for a new transparent low dose contraceptive
patch (ethinylestradiol/gestodene). Acino will be manufacturing the patch at its new
pharmaceutical manufacturing plant for transdermal therapeutic systems at the company
site in Miesbach (Germany).